|
Jay Hagan, Managing Director Amgen Ventures Jay Hagan joined Amgen in 1998 and is currently the Managing Director for Amgen Ventures, the Company’s corporate venture capital fund. He oversees and directs the fund’s investment in early-stage biotechnology companies focused on discovering and developing human therapeutics. Mr. Hagan previously was director of Corporate Development at Amgen where he had responsibility for M&A, as well as support of significant corporate driven alliance initiatives. He has led a number of notable transactions including the acquisitions of Tularik and Immunex as well as the sale of the Novantrone business. Before joining Amgen, Mr. Hagan worked for Genzyme Corporation, where he was a biochemical engineer. Mr. Hagan received his Master’s in Business Administration from Northeastern University and his B.S. in Physiology and Neuroscience from UC San Diego. | 